GlassScriptPhysician profile
Teri Engelberg
NPI 1083682959
$21,100.62
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $2,247 · 2021: $18K · 2022: $255 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $113.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $17,923.50 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $704.65 | 2019-2024 | Austedo Xr |
| Amgen INC. | $387.91 | 2019-2021 | |
| Sk Life Science, INC. | $243.88 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $239.21 | 2021-2022 | |
| Abbvie INC. | $198.11 | 2021 | |
| Allergan, INC. | $150.99 | 2019-2021 | |
| Silk Road Medical, INC. | $147.15 | 2019 | |
| Genentech USA, INC. | $145.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $116.25 | 2019-2021 | |
| Emd Serono, INC. | $110.87 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $107.03 | 2020-2021 | |
| Biogen, INC. | $101.63 | 2019-2021 | |
| Zyla Life Sciences, INC. | $69.70 | 2020 | |
| Grt US Holding, INC. | $54.77 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $50.54 | 2020 | |
| Mdd US Operations, LLC | $47.67 | 2019-2020 | |
| Almatica Pharma LLC | $46.52 | 2021 | |
| Arbor Pharmaceuticals, INC. | $42.09 | 2020 | |
| Lundbeck LLC | $36.99 | 2020-2021 | |
| Genzyme Corporation | $35.68 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.90 | 2019 | |
| Amneal Pharmaceuticals LLC | $21.58 | 2021 | |
| Supernus Pharmaceuticals, INC. | $20.97 | 2020 | |
| Neurelis, INC. | $19.02 | 2021 | |
| Kyowa Kirin, INC. | $18.87 | 2020 | |
| Lilly USA, LLC | $18.35 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Engelberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.